MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing (Q39533432)

12 September 2017

MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing (English)

1 reference

12 September 2017

0 references

0 references

1 reference

Lei Bao

1

1 reference

PubMed ID

21626030

12 September 2017

Kimberly Dunham

series ordinal

2

1 reference

PubMed ID

21626030

12 September 2017

Kenneth Lucas

series ordinal

3

1 reference

12 September 2017

28 May 2011

1 reference

Cancer Immunology, Immunotherapy

12 September 2017

1 reference

12 September 2017

60

1 reference

12 September 2017

1299-1307

1 reference

12 September 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1037-z

12 September 2017

0 references

cites work

Neuroblastoma: biological insights into a clinical enigma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Viral strategies of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

DNA Methylation and Gene Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Future directions for the use of hypomethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

In vitro antigenic modulation of human neuroblastoma cells induced by IFN-gamma, retinoic acid and dibutyryl cyclic AMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Clinical Use of Interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

Expression of cancer/testis (CT) antigens in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1037-Z

10.1007/S00262-011-1037-Z

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference

PubMed ID

21626030